Cargando…
Visfatin and Subclinical Atherosclerosis in Type 2 Diabetes: Impact of Cardiovascular Drugs
Background and Objectives: The role of adipokines in the development of atherosclerosis in type 2 diabetes (T2DM) has not yet been fully elucidated. The effects of drugs on adipokine concentrations have only been evaluated in very few studies, although they may be of clinical importance. This study...
Autores principales: | Kärberg, Kati, Forbes, Alastair, Lember, Margus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386106/ https://www.ncbi.nlm.nih.gov/pubmed/37512134 http://dx.doi.org/10.3390/medicina59071324 |
Ejemplares similares
-
Predictors of quality of life of patients with type 2 diabetes
por: Kalda, Ruth, et al.
Publicado: (2008) -
Visfatin/Nampt: An Adipokine with Cardiovascular Impact
por: Romacho, Tania, et al.
Publicado: (2013) -
Type 2 Diabetes Mellitus Coincident with Clinical and Subclinical Thyroid Dysfunctions Results in Dysregulation of Circulating Chemerin, Resistin and Visfatin
por: Tabandeh, Mohammad Reza, et al.
Publicado: (2023) -
Impact of hypertension on various markers of subclinical atherosclerosis in early type 2 diabetes
por: Alatab, Sudabeh, et al.
Publicado: (2014) -
Family doctors' knowledge and self-reported care of type 2 diabetes patients in comparison to the clinical practice guideline: cross-sectional study
por: Rätsep, Anneli, et al.
Publicado: (2006)